StoneX Group’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

StoneX Group’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.54K	Buy	+42,120	New	+$4.46K	﹤0.01%	900

Other funds holding DMAAR

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Hudson Bay Capital Management

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

Clear Street New York $24.6B AUM 56.26% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Toronto Dominion Bank

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

StoneX Group's DMAAR Position: Q1 2026 in Review

StoneX Group opened a new position in Drugs Made In America Acquisition Corp Rights (DMAAR) in Q1 2026: 42,120 shares worth $2.54K. The stake represents ﹤0.01% of the portfolio and ranks #900 among its holdings.

35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

StoneX Group held 42,120 shares of Drugs Made In America Acquisition Corp Rights worth $2.54K as of Q1 2026.
Drugs Made In America Acquisition Corp Rights was a new StoneX Group position in Q1 2026.
Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of StoneX Group's portfolio in Q1 2026, its #900 holding.
35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.